Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06693531
- Locations
- 🇺🇸
Boston Specialists, Boston, Massachusetts, United States
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT06669234
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT06669247
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT06665828
Compassionate Use of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab
- Conditions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06631677
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT06608901
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06602739
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
🇨🇦Clinique de Specialisee en Allergie de la Capitale, Quebec, Canada
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT06593600
- Locations
- 🇺🇸
North County Neurology Associates, Carlsbad, California, United States
🇺🇸Innovative Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Southern California Heart Specialists, Pasadena, California, United States
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT06602726
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦Red Maple Trials Inc., Ottawa, Ontario, Canada
🇨🇦Clinique de Specialisee en Allergie de la Capitale, Quebec, Canada
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 369
- Registration Number
- NCT06585410